The below-mentioned biotech stocks have made significant strategic progress in the recent past, making investors zoom in a bit more on these stocks. Let’s take a quick look at each one of them.
Starpharma Holdings Limited (ASX: SPL)
A leading developer of dendrimer product, Starpharma Holdings Limited (ASX: SPL) has two core development programs; VivaGel® portfolio and DEP® drug delivery platform. Recently, the company’s VivaGel® BV was officially launched in Australia by Aspen, addressing a global unmet medical need.
In April 2019, the company met with the US FDA to clarify and address their request for confirmatory data with regards to the approval of VivaGel® BV in the US. For the half-year ended 31st December 2018, the company reported a loss of $7.3 million and ended the period with a cash position of $44.4 million.
In the past six months, the share price of Starpharma Holdings decreased by 20.00% as on 9th May 2019. SPL’s shares last traded at $1.295, with a market capitalisation of circa $490.64 million (AEST 04:00 PM, 9th May 2019).
Mesoblast Limited (ASX: MSB)
A leading developer of innovative cellular medicines, Mesoblast Limited (ASX: MSB) recently announced that the US FDA has agreed to a rolling review of the company’s biologic license application for its cell therapy in children with steroid-refractory acute graft versus host disease, which is a life-threatening complication of bone marrow transplant in patients.
In March 2019, the International Center for Health Outcomes and Innovation Research (InCHOIR) and Mesoblast entered into a Memorandum of Understanding (MOU) to conduct a confirmatory clinical trial using Mesoblast’s product candidate Revascor (MPC-150-IM), demonstrating the company’s shared vision to confirm its observations of a reduction in major gastrointestinal bleeding episodes and associated hospitalisations in LVAD patients.
For the half year ended 31 December 2019, the company reported total revenues of $13.5 million.
In the past six months, the share price of Mesoblast Limited decreased by 31.19% as on 9nd May 2019. MSB’s shares last traded at $1.535, with a market capitalisation of circa $747.94 million (AEST 04:00 PM, 9th May 2019).
Immutep Limited (ASX: IMM)
A biotechnology company, Immutep Limited (ASX: IMM) has made significant progress in its clinical trials, which includes Phase IIb AIPAC clinical trial, Phase II TACTI-002 clinical trial and TACTI-mel Phase I clinical study.
Till date, the company enrolled around 211 patients in Phase IIb AIPAC clinical trial, which is being conducted at 33 clinical trial sites across Germany, the UK, France, Hungary, Belgium, Poland and the Netherlands.
Furthermore, the company enrolled 15 patients in Immutep’s Phase II TACTI-002 clinical trial, which includes 11 patients in the first line non-small cell lung cancer (NSCLC) cohort.
For the half year ended 31st December 2019, the company reported a net loss of $8.678 million.
In the past six months, the share price of Immutep Limited decreased by 39.58% as on 9th May 2019. IMM’s shares last traded at $0.030, with a market capitalisation of circa $98.12 million (AEST: 01: 15 PM, 9th May 2019).
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.